Study of BBP-418 in Patients With LGMD2I

LGMD2I Clinical Trial

Official title:
An Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003)

Status Active, not recruiting

Clinical Trial Summary

BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.

Clinical Trial Description

This is an open label study in ambulatory and non-ambulatory subjects with LGMD2I (also known as LGMD R9) previously enrolled in the natural history Study MLB-01-001. This is a study to determine the safety and tolerability of ascending dose levels of BBP-418 in those subjects. ;

Study Design

Related Conditions & MeSH terms

LGMD2I

Clinical Trial Details

NCT number	NCT04800874
Study type	Interventional
Source	ML Bio Solutions, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 18, 2021
Completion date	November 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05989620` - Long-Term Development of Muscular Dystrophy Outcome Assessments
Recruiting	`NCT04001595` - Global FKRP Registry
Recruiting	`NCT05230459` - A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)	Phase 1/Phase 2
Completed	`NCT02841267` - A Trial of PF-06252616 in Ambulatory Participants With LGMD2I	Phase 1/Phase 2
Active, not recruiting	`NCT03842878` - Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I